Skip to content
Companies

Enveric Biosciences

Non-hallucinogenic neuroplasticity drugs for depression

Raised to date

$5M

of $5M offered across 1 Form D filing

Investors
4
Last filed
May 4, 2026

About

Enveric Biosciences is a clinical-stage biotechnology company developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders such as depression, anxiety, and addiction. Its compounds are designed to promote neuroplasticity without the hallucinogenic effects associated with classical psychedelics, so they can be prescribed and taken on an outpatient basis. Discovery runs through the company's proprietary Psybrary platform, which has generated a portfolio of protected novel chemical structures. Enveric has no approved products; its lead candidate EB-003 is advancing toward an IND filing with first-in-human trials planned for 2026.

Designs neuroplastogens that engage psychedelic-adjacent receptor targets (EB-003 selectively engages both 5-HT2A and 5-HT1B) while removing the hallucinogenic effect, enabling a conventional take-home prescription model rather than supervised in-clinic dosing.

Funding

  • EquityFiled May 4, 2026Form D
    $5M/ $5M

Product

EB-003

Central nervous system drug candidate

Lead small-molecule neuroplastogen candidate, the first known compound designed to selectively engage both the 5-HT2A and 5-HT1B receptors. It is being advanced toward an FDA pre-IND meeting and IND submission, with first-in-human trials planned for 2026 in difficult-to-treat mental health disorders.

  • Dual 5-HT2A and 5-HT1B receptor engagement
  • Non-hallucinogenic neuroplastogen profile supported by recent preclinical data
  • Oral small molecule intended for a take-home prescription model

Built for

Patients with difficult-to-treat neuropsychiatric conditions including depression, anxiety, and addiction, reached through prescribing psychiatrists and neurologists; near-term counterparties are pharmaceutical partners and public-market investors.

People on file